Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lamacchia, O."'
Autor:
Penno G., Solini A., Orsi E., Bonora E., Fondelli C., Trevisan R., Vedovato M., Cavalot F., Zerbini G., Lamacchia O., Nicolucci A., Pugliese G., Laviola L.
Publikováno v:
BMC Medicine, Vol 19, Iss 1, Pp 1-13 (2021)
BMC Medicine
BMC Medicine
Background It is unclear whether insulin resistance (IR) contributes to excess mortality in patients with type 2 diabetes independent of diabetic kidney disease (DKD), which is strongly associated with IR and is a major risk factor for cardiovascular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67fb41f0182f5ecec4a47202ea6afed1
http://hdl.handle.net/10281/310207
http://hdl.handle.net/10281/310207
Autor:
Fadini, G. P., Sciannameo, V., Franzetti, I., Bottigliengo, D., D'Angelo, P., Vinci, C., Berchialla, P., Arena, S., Buzzetti, R., Avogaro, A., Consoli, A., Formoso, G., Grossi, G., Pucci, A., Sesti, G., Andreozzi, F., Capobianco, G., Gatti, A., Bonadonna, R., Zavaroni, I., Cas, A. D., Felace, G., Volsi, P. L., Leto, G., Sorice, G. P., Morano, S., Bossi, A. C., Duratorre, E., Morpurgo, P. S., Orsi, E., Querci, F., Boemi, M., D'Angelo, F., Petrelli, M., Aimaretti, G., Karamouzis, I., Cavalot, F., Saglietti, G., Cazzetta, G., Cervone, S., Devangelio, E., Lamacchia, O., Di Benedetto, A., Frittitta, L., Giordano, C., Piro, S., Rizzo, M., Chianetta, R., Mannina, C., Anichini, R., Penno, G., Solini, A., Fattor, B., Bonora, E., Cigolini, M., Lapolla, A., Chilelli, N. C., Poli, M., Simioni, N., Frison, V.
Publikováno v:
Diabetes, Obesity & Metabolism
Aims According to cardiovascular outcome trials, some sodium‐glucose contransporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69ce227387e054af04ea1aad47238be7
http://hdl.handle.net/11577/3302856
http://hdl.handle.net/11577/3302856
Autor:
Fadini, Gian Paolo, Bottigliengo, Daniele, D'Angelo, Federica, Cavalot, Franco, Bossi, Antonio Carlo, Zatti, Giancarlo, Baldi, Ileana, Avogaro, A, Consoli, A, Formoso, G, Grossi, G, Pucci, A, Sesti, G, Andreozzi, F, Capobianco, G, Gatti, A, Bonadonna, R, Zavaroni, I, Cas, Ad, Felace, G, Volsi, Pl, Buzzetti, R, Leto, G, Sorice, Gp, D'Angelo, P, Morano, S, Bossi, Ac, Duratorre, E, Franzetti, I, Morpurgo, Ps, Orsi, E, Querci, F, Boemi, M, D'Angelo, F, Petrelli, M, Aimaretti, G, Karamouzis, I, Cavalot, F, Saglietti, G, Cazzetta, G, Cervone, S, Devangelio, E, Lamacchia, O, Arena, S, Benedetto, Di, A, Frittitta, L, Giordano, C, Piro, S, Rizzo, M, Chianetta, R, Mannina, C, Anichini, R, Penno, G, Solini, A, Fattor, B, Bonora, E, Cigolini, M, Lapolla, A, Chilelli, Nc, Poli, M, Simioni, N, Frison, V, Vinci, C
Publikováno v:
Diabetes Therapy
Introduction DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice. Methods This was a multicent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaf78f9c28b3a572d3a1d52646fe4120
http://hdl.handle.net/11577/3287224
http://hdl.handle.net/11577/3287224
Autor:
Saglimbene, V., Palmer, S. C., Ruospo, M., Natale, P., Maione, A., Nicolucci, A., Vecchio, M., Tognoni, G., Craig, J. C., Pellegrini, F., Lucisano, G., Hegbrant, J., Ariano, R., Lamacchia, O., Sasso, A., Morano, S., Filardi, T., De Cosmo, S., Pugliese, G., Procaccini, D. A., Gesualdo, L., Palasciano, G., Johnson, D. W., Tonelli, M., Strippoli, G. F. M., Cignarelli, M., Di Mauro, M. D., Tonolo, G., Adinolfi, L. E., Gigante, A., Carboni, L., Anichini, R., Marino, C., Querques, M., Manfrini, S., Cianciaruso, B., Grandaliano, Giuseppe, Prato, S. D., Giorgino, F., Perin, P. C., Malberti, F., Nardo, A., Invitti, C., Panettieri, I., Bono-mini, M., Sesti, G., Altomare, E., Giordano, R., Iacono, A., Lusenti, T., Jovane, C., Zavaroni, I., Vernaglione, L., Grosso, J., Stratta, P., Andriani, A., Montanaro, A., Ciaula, A. D., Triolo, G., Santoro, A., Spada, S., Benedetto, A. D., Borzi, V., Tortul, C., Schiavoni, M., Cavalera, C., Iannarelli, R., Mileti, G., Tardi, S., Di Rosa, S.
Background The comparative effectiveness of treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or their combination in people with albuminuria and cardiovascular risk factors is unclear. Methods In a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb63af36dffbc116702c60828ac4b9cc
http://hdl.handle.net/20.500.11769/496942
http://hdl.handle.net/20.500.11769/496942
Autor:
Massimiliano Copetti, Claudia Menzaghi, Tommaso Mazza, Maria Giovanna Scarale, Alessandra Antonucci, Salvatore De Cosmo, Rosa Di Paola, Marina Cardellini, Viviana Casagrande, Rossella Menghini, Vincenzo Trischitta, Massimo Federici, Olga Lamacchia, Lucia Salvemini, Gianluigi Ferrazza
Context Type 2 diabetes (T2D) shows a high mortality rate, partly mediated by atherosclerotic plaque instability. Discovering novel biomarkers may help identify high-risk patients who would benefit from more aggressive and specific managements. We re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abaa39db81e2ab7070c2702374067ca9
Autor:
Franco Cavalot, Antonio Nicolucci, Giuseppe Pugliese, Olga Lamacchia, Cecilia Fondelli, Giuseppe Penno, Anna Solini, Marco Scardapane, Roberto Trevisan, Enzo Bonora, Monica Vedovato, Emanuela Orsi
Publikováno v:
Diabetologia. 61(11)
Aims/hypothesis: Non-albuminuric renal impairment has become the prevailing diabetic kidney disease (DKD) phenotype in individuals with type 2 diabetes and an estimated GFR (eGFR)